Chimeric Antigen Receptor-T (CAR-T) Cells as “Living Drugs”: A Clinical Pharmacist Perspective

Table 2

Overview of approved CAR-T cell products.

	Tisagenlecleucel	Axicabtagene ciloleucel	Brexucabtagene autoleucel	Lisocabtagene maraleucel	Idecabtagene vicleucel	Ciltacabtagene autoleucel
Proprietary name	Kymriah™	Yescarta™	Tecartus™	Breyanzi™	Abecma™	Carvykti™
Biological	CTL019 [65, 74, 75]	KTE-C19 [66, 76–78]	KTE-X19 [79]	JCAR017 [67, 80]	bb2121 [81]	LCAR-B38M [68, 82]
Target	CD19	CD19	CD19	CD19	BCMA	BCMA
Costimulation	4-1BB	CD28	CD28	4-1BB	4-1BB	4-1BB
Signalling domain	CD3ζ	CD3ζ	CD3ζ	CD3ζ	CD3ζ	CD3ζ
Vector	Lentiviral	Retroviral	Retroviral	Lentiviral	Lentiviral	Lentiviral
Indication	Paediatric 3L+ B-ALL; Young adult 3L+ B-ALL; 3L+ DLBCL; 3L+ FL	3L+ DLBCL; 3L+ PMBCL; 4L+ FL	3L+ MCL; Adult 3L+ B-ALL	3L+ DLBCL; 3L+ PMBCL; 3L+ FL	4L+ MM	4L+ MM
MA trial	ELIANA; JULIET	ZUMA-1; ZUMA-5	ZUMA-2; ZUMA-3	TRANSCEND NHL 001	KarMMa-3	CARTITUDE-1
Approval	2017 (FDA); 2018 (EMA)	2017 (FDA); 2018 (EMA)	2020 (FDA); 2020 (EMA)	2021 (FDA); 2022 (EMA)	2021 (FDA); 2022 (EMA)	2022 (FDA); 2022 (EMA, positive CHMP opinion received)

Key: 3L+ = three or more lines of failed treatment; B-ALL = B-cell acute lymphoblastic leukaemia after three lines or more lines of therapy; 4L+ = four or more lines of failed treatment; DLCBL = diffuse large cell B cell lymphoma; FL = follicular lymphoma; PMBCL = primary mediastinal large B-cell lymphoma; MCL = mantle cell lymphoma; MM = multiple myeloma; EMA = European Medicines Agency; FDA = Food and Drug Administration.